New agents for the treatment of acute myelogenous leukemia are discussed that reflect different treatment mechanisms. These include histone acetylation, angiogenesis inhibition, protein kinase inhibitors, and a novel retinoid. Efficacy and safety in phase I and phase II trials reviewed, as well as the problems involved in crossing over from treatment of solid tumors to blood disorders. Leukemia (2000) 14, 488-490.
Introduction
Different mechanisms for the treatment of acute myelogenous leukemia (AML) are being investigated, leading to what may be a variety of promising treatments. Among these are histone acetylation, with a focus on phenylbutyrate; angiogenesis inhibition, including thalidomide and SU5416; protein kinase inhibitors, including bryostatin and UCN-01; and finally, a novel retinoid, fenretinide. In addition to their development, there is a brief discussion about the issue of how to best evaluate their efficacy and make decisions about taking them forward in development.
Histone acetylation
The concept of histone acetylation has become familiar recently, and particularly in the last year. Many papers have been published about its role in gene expression and in leukemia. [1] [2] [3] [4] [5] [6] [7] Histone acetylation modulates higher ordered chromatic structure through the acetylation of lysine tails. This causes the loosening of DNA histone contacts, leading to increased accessibility of transcription factors and subsequently an increased gene expression. Coactivator histone acetylase complexes that form on DNA promoters will promote gene expression while, conversely, corepressor histone deacetylase complexes inhibit gene expression. 8 Histone deacetylase plays a very important role in leukemia. It has been shown that the mutant fusion proteins that occur in leukemia recruit corepressor histone deacetylase complexes. This occurs for both the PML-RAR 15; 17 translocation and the PLZF-RAR 11; 17 translocation, which is also associated with retinoid resistance in promyelocytic leukemia (PML).
1-4 A number of papers have shown the importance of these mutant proteins in recruiting histone deacetylase complexes. In addition, in AML-1/ETO leukemia, that mutant fusion protein also recruits histone deacetylase complexes. 6, 9 Furthermore, in both instances it was shown that trichostatin A, a very toxic antifungal which is also an inhibitor of histone deacetylase, can overcome transcriptional repression in leukemic cells. In addition to trichostatin A, other microbial metabolites which are also histone deacetylase inhibitors have been studied and some are nearing the clinic. Depsipeptide, which was first developed by Michael Grever while he was still at the NCI, is one that is currently in clinical trials. Acting at submicromolar concentrations, these agents are very potent. 10 Butyrates under development, including sodium phenylbutyrate which is active in millimolar concentrations, have also been shown to inhibit histone deacetylase. 11 Finally, there are hybrid polar compounds, that were recently described by the group at Memorial Sloan-Kettering, one of which will be entering clinical trials in the near future. These are active at submicromolar concentrations.
Sodium phenylbutyrate (NSC 657802), a phenyl fatty acid with many mechanisms of action, works primarily by promoting glutamine excretion, making it less available for nucleic acid and protein synthesis.
11 This is the rationale for using it in urea cycle disorders. In addition, it inhibits protein isoprenylation, which is necessary, for example, for RAS function. It activates a peroxisome proliferator activator receptor (PPAR), an important growth regulator. Finally, it has been shown to induce expression of nonexpressed silenced genes. A number of phase I trials have been completed and maximum tolerated doses (MTD) have been established for several schedules of administration. Because of its weak histone deacetylase activity and the fact that at the MTD we are only beginning to reach the levels necessary for in vitro activity, sodium phenylbutyrate may not have much clinical use. However, it is very useful as a way of demonstrating 'proof of principle' for a number of different concepts.
It has been found that when retinoic acid (RA) and phenylbutyrate are combined, there is a much greater increase in differentiation. 12 On the basis of this finding, coupled with the histone deacetylase activity of these two drugs, we will be sponsoring trials of the combination. There are possible clinical applications as well. Ray Warrell at Memorial Sloan-Kettering recently described a 13-year-old female with resistant PML who had failed several different therapies, including high-dose ara-C, allogeneic transplant, arsenic, and all-trans retinoic acid (ATRA). The proposed protocol was dose escalation of ATRA to 45 mg/m 2 twice a day plus phenylbutyrate to 210 mg/kg i.v. twice a day. The cycle was 3 weeks on therapy and 3 weeks off. Remarkably, there was a clinical and molecular CR before the end of the second cycle and the patient remained in continuous remission for over 6 months before subsequently relapsing. This clinical response was corroborated through molecular phenotyping and was associated with acetylation of histone-3 and histone-4 in both blood and bone marrow at various stages of treatment.
DNA methylation and its relationship to histone acetylation are worthy of mention here. DNA promoter methylation recruits the histone deacetylase to block gene expression during transcription. This is mediated by binding of the protein MeCP2. 13, 14 There are exciting preclinical data from Steve Baylin at Johns Hopkins that have shown that DNA demethylation using decitabine plus inhibition of histone deacetylase with Trichostatin A synergized in re-expressing genes that were silenced in cancer. 15 On the basis of these observations, we plan to study this combination in clinical trials. However, due to the difficulty of obtaining decitabine, the trials will employ a combination of 5-azacytidine and phenylbutyrate.
Tumor angiogenesis
Folkman proposed that recruitment and generation of new blood vessels is necessary for tumors to grow and to metastasize. 16 Interruption of this process through angiogenesis inhibition might be a powerful antitumor agent. Urinary basic FGF is elevated in half of patients with leukemia. 17 Moreover, bone marrow microvessel density and urinary basic FGF are increased in children with ALL. 18 Finally, vascular endothelial growth factor is expressed by leukemic blasts in 2/3 of patients with AML. 19 Properties of angiogenesis inhibitors include specificity for a particular step, aspect, or component in the process of neovascularization. They have a broad spectrum of antitumor activity, lack of documented resistance, are relatively nontoxic, and are potentially synergistic with other antitumor therapies. Several different targets or mechanisms of action are being looked at with a number of different agents. Inhibition of angiogenic factor activity includes inhibition of release, binding of the free circulating factor, blockade/inhibition of receptor binding, or inhibition of intracellular receptor signaling. In addition, there could be selective activity against endothelial cells. There may be direct inhibition of endothelial cell function or response, such as with thalidomide, though the mechanism is not entirely clear. Other agents may inhibit endothelial cell-specific intergrins or survival signaling. Thalidomide is already under study at MD Anderson for leukemia and multiple myeloma.
Thalidomide has been studied in a number of phase II trials: as a single agent in hormone refractory prostate cancer, breast cancer, AIDS-associated Kaposi's sarcoma, and glioma (James Pluda, personal communication). Activity has been seen in all these applications. The Sugen compound, SU5416, is a chemically modified small organic molecule that specifically inhibits vascular endothelial growth factor signaling through the Flk-1 receptor in endothelial cells. In vivo, SU5416 has been shown to inhibit a variety of tumors. A phase I trial is currently under way looking at solid tumors as well as leukemia.
Protein kinase inhibitors
One of the earliest of the protein kinase C (PKC) inhibitors, bryostatin, was isolated by Petit in Arizona from a bryozoa (Bugula neritina). It has a 26 member macrolide ring structure, and is a potent ligand for PKC. Bryostatin activates and downregulates PKC, and is concentration-and schedule-dependent. At low concentrations there is activation of the enzyme, while at high concentrations there is down-regulation; with prolonged exposure to low concentrations, there is initial shortterm PKC activation followed by down-regulation. Myalgia is the primary dose-limiting toxicity of bryostatin. Other organ systems have been involved as well, with milder types of hematologic reactions, including thrombocytopenia and leukopenia; gastrointestinal, including nausea and vomiting; mild LFT elevations; local reactions such as phlebitis and cellulitis; and others, including headache, fatigue, rash, and fever. There are a number of combination studies under way with bryostatin. Those that are involved in leukemia or myelodysplastic syndrome include phase I trials with cytarabine, fludarabine, Leukemia and with 2-chlorodeoxyadenosine. There is also a phase II study in combination with ATRA for AML/MDS.
Another compound, UCN-01, is also a check point modulator. It is a staurosporine analogue known as 7-hydroxystaurosporine. Down-regulation or inhibition of PKC by bryostatin or UCN-01 has been shown to circumvent cytarabine resistance. 20 Research by Steve Grant at the Medical College of Virginia has found that in the HL60 cells that were made resistant to cytarabine by Bcl-2 overexpression, preincubation with bryostatin or coincubation with UCN-01 led to restoration of cytarabine-induced apoptosis. 20 Moreover, treatment with bryostatin and UCN-01 led to phosphorylation of Bcl-2 and promoted apoptosis. 
Novel retinoids
Fenretinide (4-[hydroxy] phenylretinamide; 4-HPR) is a compound that was first developed by Sporn and colleagues as a chemopreventive agent used at doses of 200-400 mg given daily. 21 In the past decade, fenretinide was found to induce apoptosis in malignant cells independent of the nuclear retinoid receptor pathway. 22, 23 Cells that lack nuclear retinoid receptors are still sensitive to its apoptotic effects. While fenretinide exhibits cytostatic effects at the lower doses that were used in the chemoprevention trials (Ͻ1 m), at higher doses Ͼ3 m, cytotoxic effects were observed. It was on this basis that its development and use is being promoted more as a cytotoxic than as a cytostatic agent. Two phase I dose escalation trials are near completion. In the adult trial, up to 10 m plasma concentrations have been achieved at dose levels of 2400-3400 mg/m 2 /day. These levels are much higher than the ones that were used in the chemoprevention trials. The major, although non-dose-limiting, toxicity has been reversible night blindness. In the pediatric trial, 3-8 m plasma concentrations have been achieved at a much lower dose level (800 mg/ m 2 /day). 24 Two cases of increased intracranial pressure have occurred, but resolved after discontinuation of the agent. Accrual continues in the pediatric study at the 1050 mg/m 2 /day dose level.
Future directions
Currently, drug development involves a dose escalation until an MTD is established. With newer agents that are directed at specific molecular targets, the goal now is to find the optimal effective dose that has the desired pharmacologic effect. An example of such an approach is the clinical development of histone deacetylase inhibitors based upon histone acetylation in leukemic cells, rather than upon a toxicity end point. In addition, new agents should be tested earlier in leukemic patients, rather than adhering to the more common practice of testing after studies in solid tumors have been performed. This frequently leads to unnecessary delays in testing promising leukemia therapies. There is a clear need to rethink early clinical trial strategies in hematologic malignancy.
